A Phase 2 interventional study of TGR-1202 and TGR-1202 + Ublituximab in Chronic Lymphocytic Leukemia and Non Hodgkin Lymphoma, sponsored by TG Therapeutics, Inc.. Terminated at 17 sites in United States. Per ClinicalTrials.gov, last updated 2022-07-21.
Sponsored by TG Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing umbralisib in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. umbralisib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 14 studies testing umbralisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 7 in phase 2, and was the 9th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →None of the 14 studies testing umbralisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →
umbralisib: first FDA approval 2021 (UKONIQ). What it is approved for, and how studies give it, is on its page →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 3
First in 2013; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 51 across the 14 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 5 most frequent:
TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 18 finished, 7 (39%) have results posted.
Among the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc., this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 13th registered.
TG Therapeutics, Inc.’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing umbralisib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among TG Therapeutics, Inc.’s 18 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Oral TGR-1202 Daily
Drug: TGR-1202
Oral TGR-1202 in combination with Ublituximab intravenous administration
Drug: TGR-1202 + Ublituximab
Oral Daily TGR-1202
Drug pages: Umbralisib · Ublituximab
Oral Daily TGR-1202 + Ublituximab IV Administration
Adverse Events of TGR-1202 and/or TGR-1202 + ublituximab treatment, including delayed toxicities
Toxicity according to the investigator (Adverse events with NCI-CTC 4.0)
Time frame: Evaluated at each planned visit through study completion, an average of 2 years
Progression-free survival of TGR-1202 and/or TGR-1202 + ublituximab treatment
Date of progression reported for each patient
Time frame: Evaluated at each planned visit through study completion, an average of 2 years
Ran from Aug 2017 to primary completion in May 2022, 57 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Umbralisib · Ublituximab
Leukemia, Lymphocytic, Chronic, B-Cell →